Actelion
-
Johnson & Johnson to buy Swiss biotech company Actelion in a $30 billion all-cash deal
Jan 26, 2017News Hour: U.S. healthcare giant Johnson & Johnson will buy Swiss biotech company Actelion in a $30 billion all-cash deal that includes spinning off Actelion’s research and development pipeline, the companies said on Thursday. The biggest...